-
OrigiMed announced its strategic partnership with Janssen
OrigiMed Co., Ltd.(“OrigiMed”) announced that the company has signed a memorandum of understanding (MoU) on strategic collaboration with Janssen (China) Research and Development Center of Johnson & Johnson (China) Investment Co., Ltd. (“Janssen”).
2021-12-03 -
The NGS based CDx Human NTRK1/2/3 Genomic Alteration Test Kit to inform treatment decisions for larotrectinib developed by OrigiMed in cooperation with Bayer was granted the NMPA Special Review Procedure for Innovative Medical Devices in China
SHANGHAI, Aug. 22, 2021 /PRNewswire/ -- OrigiMed announced that the Human NTRK1/2/3 Genomic Alteration Testing Kit has been granted the Special Review Procedure for Innovative Medical Devices by the Center for Medical Device Evaluation of NMPA.
2021-08-22 -
OrigiMed and Takeda Announced Partnership to Accelerate R&D and Commercialization of Innovative Medicines
The collaboration will develop an innovative genomic-based clinical treatment platform
2020-11-11 -
Bayer and OrigiMed reached a partnership to develop a next generation sequencing (NGS) based companion diagnostic-in vitro diagnostic (CDx-IVD) product in China for Larotrectinib, for NTRK gene fusion detection
The collaboration will begin with the development of a CDx-IVD for larotrectinib for the Chinese market. Larotrectinib is the world's first TRK inhibitor to be approved in patients with TRK gene fusion cancer in all solid tumors in the United States...
2020-04-30 -
CTONG-OrigiMed New Clinical Trial Sharing Platform Launched during the 3rd OrigiMed Summit for Cancer Discovery
SHANGHAI, May 24, 2019 /PRNewswire/ -- With fast advances in the medical industry, on May 11, 2019, the third OrigiMed Summit for Cancer Discovery: Immunotherapy and Targeted Therapy was successfully held in Guangzhou.
2019-05-24 -
OrigiMed Completes Series B Round Focusing on Creating a Comprehensive Precision Medicine Platform for Oncology
SHANGHAI, Jan. 4, 2019 /PRNewswire/ -- OrigiMed (Shanghai) Co., Ltd., (OrigiMed) has formally announced the completion of its Series B financing. This round of financing is led by Grand Flight Investment. The pre-A financing investor Wedo Capital...
2019-01-04 -
Launch of Special Chinese Big Data Platform for Cancer Genomics Informatics to Accelerate Innovation and Development of China's Precision Diagnosis and Treatment
SHANGHAI, Sept. 28, 2018 /PRNewswire/ -- On September 21, 2018, the CSCO precision medicine international session with the theme of "All-Round Research by Experts for Further Study", hosted by the Chinese Society of Clinical Oncology (CSCO) and...
2018-09-28 -
OrigiMed Collaborates with Illumina to Further Develop and Promote its Advanced Clinical Molecular Tumor Applications
SHANGHAI, July 13, 2018 /PRNewswire/ -- OrigiMed announces an agreement with Illumina in Shanghai, China. It will develop and promote its advanced molecular clinical tumor applications to the public based on the Next Generation Sequencing (NGS)...
2018-07-13